Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 16, Issue 5, Pages 275-276Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41571-018-0155-3
Keywords
-
Categories
Funding
- Dutch Cancer Society/KWF [10300]
- German Research Foundation (DFG) [124/9-1]
- Christian-Albrechts-University
Ask authors/readers for more resources
The first-in-human study of anti-CD47 antibodies blocking CD47-SIRP alpha interactions in combination with rituximab in patients with non-Hodgkin lymphoma shows encouraging clinical responses accompanied with mild levels of toxicity. Inhibition of the CD47-SIRP alpha interaction might provide a generic method of promoting the effects of antitumour antibodies in a variety of cancer types. This reveals, for the first time, an innate immune checkpoint as a bona fide target for therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
